{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ADD&page=35",
    "query": {
      "condition": "ADD",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 2227,
    "total_pages": 223,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ADD&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ADD&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T17:42:34.286Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03937479",
      "title": "Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 416,
      "start_date": "2019-05-01",
      "completion_date": "2019-11-15",
      "has_results": true,
      "last_update_posted_date": "2020-11-20",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 50,
      "location_summary": "Anniston, Alabama • Fullerton, California • Los Angeles, California + 44 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lafayette",
          "state": "Colorado"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03937479"
    },
    {
      "nct_id": "NCT01654250",
      "title": "NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "NWP09",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 90,
      "start_date": "2012-07",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2016-02-03",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 9,
      "location_summary": "Little Rock, Arkansas • Huntington Beach, California • Irvine, California + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01654250"
    },
    {
      "nct_id": "NCT07198074",
      "title": "Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Endometrial Carcinoma",
        "Recurrent Endometrial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 255,
      "start_date": "2026-01-27",
      "completion_date": "2028-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 304,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 227 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07198074"
    },
    {
      "nct_id": "NCT07661823",
      "title": "QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asperger's Disorder",
        "Asperger Disorder",
        "Autism Disorder",
        "Autism",
        "ADHD - Attention Deficit Disorder With Hyperactivity",
        "ADHD",
        "ASD",
        "Alcohol Abuse/Dependence",
        "Alcohol Addiction",
        "Alcohol and Other Drug Use Disorders",
        "Alcohol and Other Substance Use Prevention",
        "Gambling Addiction",
        "Gambling Disorder",
        "Sex Abuse",
        "Sex Behavior",
        "Sex Crimes",
        "Sex Disorder",
        "Sex Disorders",
        "Gender Dysphoria, Adult",
        "Eating Behavior Disorders",
        "Narcotic-Related Disorders",
        "Narcotic Addiction",
        "Narcissism",
        "Psychiatric Disorder",
        "Psychedelic Effects in Healthy Volunteers",
        "Psychedelic Experiences",
        "Psychedelic Drug Dependence",
        "Marijuana Use Disorder",
        "Marijuana Abuse and Dependence",
        "Smoking (Tobacco) Addiction",
        "Smoking Among Youth",
        "Smoking Abstinence",
        "Abstinence, Sex",
        "Opiate Substitution Treatment",
        "Opioid Abuse (Disorder)",
        "Opioid Abuse and Addiction",
        "Cocaine Abuse",
        "MDMA ('Ecstasy')",
        "Addiction Disorders",
        "Homeless and Low Incomes People, Refugees",
        "Homelessness",
        "Reliability and Validity",
        "Anger Problems",
        "Child Abuse, Sexual"
      ],
      "interventions": [
        {
          "name": "AI City Hall Project (AIhealth4u - Public Health Central)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "AI City Hall Project (QAIAx Microcity A - AI Public Health Central)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Veterans Recovery Network Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "17 Years to 99 Years"
      },
      "enrollment_count": 1000000,
      "start_date": "2026-10-01",
      "completion_date": "2045-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07661823"
    },
    {
      "nct_id": "NCT03046485",
      "title": "Use of Self-management Group to Improve Quality of Life in Patients With Low Vision",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Self management program 'Living with Vision Loss'",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "55 Years to 95 Years"
      },
      "enrollment_count": 0,
      "start_date": "2007-05",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-02-08",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03046485"
    },
    {
      "nct_id": "NCT05496140",
      "title": "Remote School-Home Program to Improve Youth Attention and Behavior in Mexican Students",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "ADHD",
        "Oppositional Defiant Disorder"
      ],
      "interventions": [
        {
          "name": "CLS-R-FUERTE",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2022-09-01",
      "completion_date": "2023-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-15",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05496140"
    },
    {
      "nct_id": "NCT02041715",
      "title": "Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Virus Infection"
      ],
      "interventions": [
        {
          "name": "TKM-100802 for Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arbutus Biopharma Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 21,
      "start_date": "2014-01",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-08-07",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02041715"
    },
    {
      "nct_id": "NCT04790513",
      "title": "Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "lerodalcibep",
          "type": "BIOLOGICAL"
        },
        {
          "name": "evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "alirocumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "LIB Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2021-04-22",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-03-29",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04790513"
    },
    {
      "nct_id": "NCT07223515",
      "title": "HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Foot Ulcer (DFU)",
        "Venous Leg Ulcers (VLUs)",
        "Pressure Ulcers, Bedsores, Decubitus Ulcer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Dynamic Medical Services dba Acesso Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2025-10-24",
      "completion_date": "2025-11",
      "has_results": false,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 2,
      "location_summary": "Novi, Michigan • Murfreesboro, Tennessee",
      "locations": [
        {
          "city": "Novi",
          "state": "Michigan"
        },
        {
          "city": "Murfreesboro",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223515"
    },
    {
      "nct_id": "NCT01177774",
      "title": "Assessment of Children With Tic Onset in the Past 6 Months",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Tourette Syndrome",
        "Tourette's Disorder",
        "Chronic Motor or Vocal Tic Disorder",
        "Transient Tic Disorder",
        "Tic Disorders",
        "Provisional Tic Disorder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "5 Years to 10 Years"
      },
      "enrollment_count": 99,
      "start_date": "2010-08",
      "completion_date": "2023-07-13",
      "has_results": false,
      "last_update_posted_date": "2023-11-27",
      "last_synced_at": "2026-10-30T17:42:34.286Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01177774"
    }
  ]
}